Introduction and Objective: Cardiovascular disease (CVD) is the leading cause of death in the US. The i3C risk score is the only predictive model of 35-year fatal/non-fatal cardiac events in adolescents and young adults (AYA), but its reliability is unknown. We evaluated the i3C score test-retest reproducibility over short and long-term intervals.Methods: In a pooled cohort analysis, we calculated i3C scores in 210 AYA with two consecutive visits grouped by time to follow-up: G1 (≤1y), G2 (1-3y), G3 (>3y). To further validate the long-term interval, we evaluated reliability in a subset (n=36) with 3 consecutive visits. The i3C score is calculated by z-scores of 5 CVD factors (BMI, systolic blood pressure (SBP), triglyceride (TG), total cholesterol, and smoking status). Pearson correlation coefficients, adjusted for race and diagnosis, and Bland Altman analysis were derived to evaluate agreement.Results: Baseline demographics and metabolics were similar by group (54% female, 50% White, 58% with overweight/obesity, age 14.3 ± 1.8 years, total cholesterol: (154±29 mg/dL), BMIz: (1.34 ± 2.00), SBPz: (0.53 ± 1.1), TG: (79.5 ± 41.3 mg/dL), (mean±SD)). Baseline and follow-up i3C score strongly correlated in G1 and G2 (r>0.9, P<0.001) with good agreement, but were lower in G3 and the subset.Conclusion: Overall, the i3C risk score had good one-to-three-year reproducibility in AYA and may need to be re-assessed after >3years.
I.N. Kacker: None. S.B. Glaros: None. N.A. Macheret: None. S.L. Cantor: None. T.P. Massie: None. N. Malandrino: None. L. Mabundo: None. J.A. Yanovski: Research Support; Rhythm Pharmaceuticals, Inc, Soleno Therapeutics, Versanis, Hikma Therapeutics. S.T. Chung: None.
Source link
Leave a Reply